Curadev

Curadev Pharma possesses a portfolio of small-molecule drug discovery biotechnology and exciting research programs, generating patent-protected drug candidates. Established in 2010, Curadev is renowned for its pre-determined target selection and high-quality, data-driven programs. Their initiatives aim to improve diseases by incorporating the latest developments in new drug research. They have successfully created and patented small-molecule immunotherapy innovations, subsequently licensing these patents.